目的 观察复方口服避孕药妈富隆(Marvelon)对骨矿物质密度的影响.方法 随机选择46例年龄为25～40岁女性应用妈富隆药物24个月;随机选择53例年龄为25～40岁从未应用激素避孕药女性做对照;应用双能X线吸收法测量腰椎和股骨颈骨矿物质密度.结果 用药组用药2年后腰椎和股骨颈平均骨矿物质密度从基础值1.110(0.114g/cm2),0.917(0.088g/cm2)下降到1.106(0.109g/cm2)和0.902(0.091g/cm)2,分别下降了0.36%和1.64%;与对照组相比骨矿物质密度无显著性差异(腰椎t=0.097,股骨颈t=0.516,均P>0.05).结论 年龄为25～40岁女性应用妈富隆避孕药与非激素避孕者相比,其骨矿物质密度无明显差异.%Objective To investigate effect of combined oral contraceptive marvelon (desogestreL/ethinylestradiol) on bone mineral density (BMD) of women of childbearing age. Methods 46 women aged 2540 years were randomly selected in the study group and were given marvelon for 24 months and 53 women in same age who didn' t use any hormonal contraceptives were as controls. BMDs of lumbar vertebrae and femoral neck of all women were detected by using dual energy X-ray absorptiometry. Restlts After 24 months of marvelon oral administration, as compared with baseline, the mean BMD in lumbar vertebrae and femoral neck of the women were decreased by 0.36％and 1.64％ , respectively, which were not significantly different from the mean BMDs in lumbar vertebrae and femoral neck of women who didn' t use marvelon ( for lumbar vertebra: t = 0. 097, for femoral neck: t = 0. 516, P ＞ 0. 05 ). Conclusion There is no significant difference in BMD between the users of marvelon and nonusers.
展开▼
